GlassScriptPhysician profile
Feras N Elhajj
NPI 1811997596
$37,063.94
in general payments reported to CMS, 2019-2025
57 companies · $791 in 2025
The $791 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $4,084 · 2021: $1,636 · 2022: $2,634 · 2023: $1,659 · 2024: $6,775 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,425 · Food and Beverage: $4,203 · Travel and Lodging: $598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,425.00 |
| Food and Beverage | $4,202.72 |
| Travel and Lodging | $598.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $21,616.26 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Eli Lilly and Company | $5,039.97 | 2019-2024 | Kisunla |
| Novo Nordisk INC | $1,873.01 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,047.47 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,000.68 | 2019-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $643.27 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $612.54 | 2019-2025 | Repatha, Otezla, Repatha |
| Supernus Pharmaceuticals, INC. | $474.32 | 2020-2024 | Qelbree, Qelbree, Xyosted |
| Pfizer INC. | $408.24 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.84 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $349.53 | 2019-2025 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $265.20 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $248.98 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $240.04 | 2021-2024 | Freestyle Libre 3, Proclaim, Prodigy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.87 | 2019-2024 | Xifaxan |
Show all 56 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Feras Elhajj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.